Ascentage Pharma Group International (AAPG)
NASDAQ: AAPG · Real-Time Price · USD
39.60
-1.21 (-2.96%)
At close: Jun 27, 2025, 4:00 PM
39.60
0.00 (0.00%)
After-hours: Jun 27, 2025, 4:04 PM EDT
AAPG Revenue
In the year 2024, Ascentage Pharma Group International had annual revenue of 980.65M CNY with 341.77% growth. Ascentage Pharma Group International had revenue of 156.90M in the half year ending December 31, 2024, with 37.70% growth.
Revenue (ttm)
980.65M CNY
Revenue Growth
+341.77%
P/S Ratio
25.17
Revenue / Employee
1,729,541 CNY
Employees
567
Market Cap
3.38B undefined
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 980.65M | 758.67M | 341.77% |
Dec 31, 2023 | 221.98M | 12.27M | 5.85% |
Dec 31, 2022 | 209.71M | 181.80M | 651.38% |
Dec 31, 2021 | 27.91M | 15.46M | 124.18% |
Dec 31, 2020 | 12.45M | -2.06M | -14.21% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
AAPG News
- 12 days ago - EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL - GlobeNewsWire
- 18 days ago - Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress - GlobeNewsWire
- 25 days ago - Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report - GlobeNewsWire
- 25 days ago - Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors - GlobeNewsWire
- 5 weeks ago - Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025 - GlobeNewsWire
- 2 months ago - Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax - GlobeNewsWire
- 2 months ago - Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin - GlobeNewsWire
- 3 months ago - Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan - Benzinga